Healthcare provider profile · identity verified

Alexander Michael Jones, D.O.

Family Practice · MANCHESTER, NH · NPI 1083092282

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	355	102
Lisinopril	Lisinopril	350	98
Simvastatin	Simvastatin	228	58
Amlodipine Besylate	Amlodipine Besylate	205	60
Metformin Hcl	Metformin Hcl	182	49
Levothyroxine Sodium	Levothyroxine Sodium	179	49
Albuterol Sulfate Hfa	Albuterol Sulfate	175	50
Omeprazole	Omeprazole	131	34
Metoprolol Succinate	Metoprolol Succinate	130	34
Gabapentin	Gabapentin	117	36
Pantoprazole Sodium	Pantoprazole Sodium	115	32
Losartan Potassium	Losartan Potassium	109	32
Hydrochlorothiazide	Hydrochlorothiazide	90	29
Zolpidem Tartrate	Zolpidem Tartrate	90	14
Lorazepam	Lorazepam	89	14
Sertraline Hcl	Sertraline Hcl	83	17
Clonazepam	Clonazepam	78	11
Furosemide	Furosemide	77	24
Duloxetine Hcl	Duloxetine Hcl	65	15
Metoprolol Tartrate	Metoprolol Tartrate	63	18
Trazodone Hcl	Trazodone Hcl	60	22
Tamsulosin Hcl	Tamsulosin Hcl	53	17
Glipizide Er	Glipizide	52	14
Ibuprofen	Ibuprofen	48	15
Fluoxetine Hcl	Fluoxetine Hcl	47	suppressed
Montelukast Sodium	Montelukast Sodium	45	12
Rosuvastatin Calcium	Rosuvastatin Calcium	43	13
Diazepam	Diazepam	41	11
Escitalopram Oxalate	Escitalopram Oxalate	39	13
Synthroid	Levothyroxine Sodium	37	suppressed
Eliquis	Apixaban	35	suppressed
Paroxetine Hcl	Paroxetine Hcl	33	suppressed
Allopurinol	Allopurinol	32	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	32	14
Meloxicam	Meloxicam	32	12
Tizanidine Hcl	Tizanidine Hcl	31	suppressed
Chlorthalidone	Chlorthalidone	30	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	30	suppressed
Pregabalin	Pregabalin	30	suppressed
Warfarin Sodium	Warfarin Sodium	30	suppressed
Atenolol	Atenolol	27	suppressed
Bupropion Xl	Bupropion Hcl	27	suppressed
Famotidine	Famotidine	27	suppressed
Alprazolam	Alprazolam	26	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	23	suppressed
Fluticasone Propionate	Fluticasone Propionate	23	suppressed
Labetalol Hcl	Labetalol Hcl	23	suppressed
Alendronate Sodium	Alendronate Sodium	22	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	21	suppressed
Citalopram Hbr	Citalopram Hydrobromide	21	suppressed
Pravastatin Sodium	Pravastatin Sodium	21	suppressed
Potassium Chloride	Potassium Chloride	20	suppressed
Ezetimibe	Ezetimibe	19	suppressed
Lovastatin	Lovastatin	19	suppressed
Meclizine Hcl	Meclizine Hcl	18	suppressed
Xolair	Omalizumab	18	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	suppressed
Buspirone Hcl	Buspirone Hcl	15	suppressed
Clonidine Hcl	Clonidine Hcl	15	suppressed
Symbicort	Budesonide/Formoterol Fumarate	15	suppressed
Ventolin Hfa	Albuterol Sulfate	15	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Mirtazapine	Mirtazapine	13	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	13	suppressed
Colchicine	Colchicine	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	12	suppressed
Ibandronate Sodium	Ibandronate Sodium	12	suppressed
Metformin Hcl Er	Metformin Hcl	12	suppressed
Torsemide	Torsemide	12	suppressed
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Olanzapine	Olanzapine	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Terbinafine Hcl	Terbinafine Hcl	11	suppressed
Tramadol Hcl	Tramadol Hcl	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error